Abstract
Serum albumin binding is an established mechanism to extend the serum half-
life of antibody fragments and peptides. The cysteine rich knob domains, isolated
from bovine antibody ultralong CDRH3, are the smallest single chain antibody
fragments described to date and versatile tools for protein engineering. Here, we
used phage display of bovine immune material to derive knob domains against
human and rodent serum albumins. These were used to engineer bispecific Fab
fragments, by using the framework III loop as a site for knob domain insertion. By
this route, neutralisation of the canonical antigen (TNFa) was retained but
extended pharmacokinetics in-vivo were achieved through albumin binding.
Structural characterisation revealed correct folding of the knob domain and
identified broadly common but non-cross-reactive epitopes. Additionally, we
show that these albumin binding knob domains can be chemically synthesised to
achieve dual IL-17A neutralisation and albumin binding in a single chemical
entity. This study enables antibody and chemical engineering from bovine
immune material, via an accessible discovery platform.
life of antibody fragments and peptides. The cysteine rich knob domains, isolated
from bovine antibody ultralong CDRH3, are the smallest single chain antibody
fragments described to date and versatile tools for protein engineering. Here, we
used phage display of bovine immune material to derive knob domains against
human and rodent serum albumins. These were used to engineer bispecific Fab
fragments, by using the framework III loop as a site for knob domain insertion. By
this route, neutralisation of the canonical antigen (TNFa) was retained but
extended pharmacokinetics in-vivo were achieved through albumin binding.
Structural characterisation revealed correct folding of the knob domain and
identified broadly common but non-cross-reactive epitopes. Additionally, we
show that these albumin binding knob domains can be chemically synthesised to
achieve dual IL-17A neutralisation and albumin binding in a single chemical
entity. This study enables antibody and chemical engineering from bovine
immune material, via an accessible discovery platform.
Original language | English |
---|---|
Article number | 1170357 |
Journal | Frontiers in Immunology |
Volume | 14 |
Publication status | Published - 12 May 2023 |